熱門資訊> 正文
FDA取消了赛诺菲甲状腺癌药物Caprelsa的REMS计划
2025-09-26 03:35
- The FDA has withdrawn the Risk Evaluation and Mitigation Strategies (REMS) program for Sanofi's (NASDAQ:SNY) medullary thyroid cancer treatment Caprelsa (vandetanib).
- The agency said that since the drug was approved in 2011, there have been no reports of heart rhythm issues or unexplained sudden deaths associated with the med in US patients.
- The FDA added that clinical data also found no patterns indicating heart rhythm problems.
- Caprelsa was developed by Genzyme, which was acquired by Sanofi in 2011 for $20.1B.
More on Sanofi
- Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript
- Historical earnings data for Sanofi
- Financial information for Sanofi
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
